FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:364 July 29, 1993 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

To the Editor: The clinical evaluation of treatments for disorders of globin-chain synthesis^1,2,3,4 has entered an exciting new era. Decisions about the design and application of future trials will dramatically influence the rapidity of the advance against sickle cell disease and beta-thalassemia. An expanding list of experimental treatments for sickle cell disease includes hydroxyurea, erythropoietin, butyrate, and bone marrow transplantation. There is a real danger, however, that in five years we will still know little about which, if any, of these approaches is best suited to a particular patient. It is difficult to enroll sufficient numbers of patients in adequate . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.